Parathyroid hormone 50micrograms/71.4microlitre dose powder and solvent for solution for injection cartridges

ContextThere is a clear link between ergocalciferol, parathyroid hormone (PTH), phosphorus, and calcium. Various randomized trials have examined the effectiveness of ergocalciferol on vitamins and minerals. However, conflicting results have been reported, and the optimal dose and duration of ergocalciferol remain unclear.ObjectiveThis systematic review and meta-analysis of RCTs aim to evaluate the effect of vitamin D2 on PTH, calcium, and phosphorus in humans.Data sourcesA comprehensive literature search was conducted with the assistance of a librarian. Independent reviewers performed searches across multiple databases, including Web of Science, Scopus, PubMed/Medline, and Embase, from their inception until September 20, 2024.Data extractionThe random-effects model, based on the DerSimonian and Laird method, was applied to compute pooled estimates of the intervention's impact on the outcomes.Data analysesA total of 26 articles were included in the meta-analysis. The pooled analysis, using a random-effects model, demonstrated a significant reduction in serum PTH concentrations (WMD, -12.77 pg/mL, 95% CI, -20.03 to -5.51, P = .001, I2 = 96%, P ConclusionVitamin D2 supplementation appears to improve serum calcium levels while decreasing PTH levels. Given the low cost and wide availability of ergocalciferol, it can be recommended, especially for older adults, to help maintain bone strength.

Abstract licence: CC BY-NC-ND

BackgroundDental implant osseointegration remains a significant clinical challenge in patients with compromised bone health, particularly in those affected by osteoporosis. Parathyroid hormone (PTH; teriparatide, PTH 1-34) is an established osteoanabolic agent with recognized impacts on bone remodelling. Its use has been proposed as an adjunctive strategy to enhance peri-implant bone regeneration under osteoporotic conditions. This updated systematic review provides evidence from preclinical evaluations of the effects of PTH supplementation on dental implant osseointegration in osteoporotic animal models. We conducted an indexed database search for studies published between January 2015 and August 2025. Outcomes were assessed using histomorphometry, microcomputed tomography, and biomechanical parameters. Methodological quality was assessed using SYRCLE's risk-of-bias tool.Highlights• Intermittent PTH administration consistently enhanced peri-implant outcomes in osteoporotic animal models. • Combination regimens outperform PTH monotherapy in osteoporotic models. • Methodological heterogeneity limits clinical translation of preclinical findings.ConclusionPreclinical evidence supports PTH supplementation as a promising adjunct to enhance peri-implant bone quality and mechanical stability in osteoporotic settings. To date, substantial heterogeneity in experimental design, outcome assessment, and study quality limits meta-analysis and translational interpretation. Standardized outcome measures and robust human trials are required before clinical applications can be considered.

Abstract licence: CC BY